Clinical significance of serum chemokine levels (CCL11 / CCL22 / TARC) in patients with type 2 diabetes

Clinical significance of serum chemokine levels (CCL11 / CCL22 / TARC) in patients with type 2 diabetes;Urine metabolomics in patients with diabetic neuropathy - Clinical significance of serum chemokine levels (CCL11 / CCL22 / TARC) in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040631

Enrollment

100

Registered

2020-06-02

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetes who have inadequate glycemic control(HbA1c between 6.5 and 12.0%) under medical treatment by dieting and exercise cure and/or drug treatment. 2)Over 20 years old and less than 80 years old 3)Sex unquestioned 4)Patients with no history of cardiovascular disease 5)No treatment or treatment with stable doses of antihypertensive and antiplatelet agents for at least 3 months prior to randomization. 6)The patient who gives a written informed

Exclusion criteria

Exclusion criteria: 1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)Patient with intolerance of medical reasons by doctor.

Design outcomes

Primary

Measure	Time frame
Clinical significance of serum chemokine levels in patient with diabetes and diabetic neuropathy.	—

Secondary

Measure	Time frame
Time of measurement: early in the morning, fasting Measurement items (LSI): CCL11 (eotaxin) CCL22 (MDC) IL-6 IL-18 Urine Metabolomics U-NGAL serum: FGF21 BDNF HMW adiponectin IL-33s TNF-R1 & -R2 Relationship with diabetic complications: peripheral neuropathy: staging, nerve conduction test, CVR-R Orthostatic hypotension (Sheron test) Timed up and Go test, Monofilament Nephropathy: eGFR UAE Retinopathy: Stage Relationship with insulin resistance: BMI, InBody, DualScan Relationship with arteriosclerosis: CAVI / ABI FMD carotid IMT Routine examination at admission + IgE + TARC + Beta-hydroxyl-butyrate + M2BPG (i Mac-2 binding protein sugar chain modification isomer), Ca, P, active Vitamin D3 Heart rate variability (HRV): CVR-R, power spectrum analysis (PSA) The severity of diabetic kidney disease Coagulation fibrinolysis system: vWF, d dimer, etc. Arterial stiffness: PWV, CAVI abdominal echo	—

Measure

Time frame

Time of measurement: early in the morning, fasting Measurement items (LSI): CCL11 (eotaxin) CCL22 (MDC) IL-6 IL-18 Urine Metabolomics U-NGAL serum: FGF21 BDNF HMW adiponectin IL-33s TNF-R1 & -R2 Relationship with diabetic complications: peripheral neuropathy: staging, nerve conduction test, CVR-R Orthostatic hypotension (Sheron test) Timed up and Go test, Monofilament Nephropathy: eGFR UAE Retinopathy: Stage Relationship with insulin resistance: BMI, InBody, DualScan Relationship with arteriosclerosis: CAVI / ABI FMD carotid IMT Routine examination at admission + IgE + TARC + Beta-hydroxyl-butyrate + M2BPG (i Mac-2 binding protein sugar chain modification isomer), Ca, P, active Vitamin D3 Heart rate variability (HRV): CVR-R, power spectrum analysis (PSA) The severity of diabetic kidney disease Coagulation fibrinolysis system: vWF, d dimer, etc. Arterial stiffness: PWV, CAVI abdominal echo

—

Countries

Japan

Contacts

Public ContactTeruo Jojima

Dokkyo Medical University Department of Endocrinology and Metabolism

jojima@dokkyomed.ac.jp0282-87-2150

Outcome results